Angiogenesis inhibitor for the treatment of endothelial cell proliferation
US6225340A · kind A · utility
4Cited by
0References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 30, 1999 |
| Grant date | May 1, 2001 |
| Priority date | — |
| Expiry date | Mar 30, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.